Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Receptor Occupancy Study of HTL0014242 in Healthy Men
NCT04462263Phase 1Completed
- Sponsor
- Nxera Pharma
- Start
- Jun 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TMP-301 in Parkinson's disease (PD), dystonia and amyotrophic lateral sclerosis (ALS), sponsored by Nxera Pharma. Primary endpoint: Receptor Occupancy Endpoint at Day 2. Started Jun 2020; status: completed.
02
Drugs
TMP-301
03
Conditions
Parkinson's disease (PD)dystoniaamyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04462263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04462263.